David Birch, AGTC (C), AGTC (F), Biogen (F), Editas (C), Iveric (C), Nacuity (C), ProQR (C), ProQR (F), Roche-4D (C), Roche-4D (F);
Lassana Samarakoon, None;
Laura Bocchino, None;
B. Melia, None;
Jacque Duncan, 4D Therapeutics (C), Acucela (F), AGTC (C), Allergan/Abbvie (F), Astellas (C), Biogen/Nightstarx Therapeutics (F), DTx Therapeutics (C), Editas (C), Eloxx (C), Eyevensys (C), Gyroscope (C), Horama (C), Neurotech USA (F), ProQR Therapeutics (C), Second Sight Medical Products (F), Sparing Vision (C), Spark Therapeutics (C), Spouse- RxSight (I), Vedere Bio (C);
Allison Ayala, None;
Isabelle Audo, Agence Nationale de la Recherche within the Investissements d'Avenir program [ANR-11-IDEX-0004-0] (F), Biogen (C), Foundation Fighting Blindness (F), Gamut Tx (C), IHU FOReSIGHT [ANR-18-IAHU-0001] (F), LABEX LIFESENSES [reference ANR-10-LABX-65] (F), MeiraGTX (C), Novartis (C), Retina France (F), Roche (C);
Janet Cheetham, Abbvie (I);
Todd Durham, None;
Alessandro Iannaccone, Acucela (F), Alia Therapeutics (S), Allergan/ Retrosense (F), Applied Genetic Technologies (C), Applied Genetic Technologies (F), Astellas (C), ClearView Healthcare Partners (C), Editas Medicine (C), Endogena (C), Evolution Medical (C), Frontera Therapeutics (C), GLG Group (C), Guidepoint Clinical (C), Gyroscope (C), Huron Consulting Group (C), IQVIA (C), Kairos Ventures (C), Rhythm Pharmaceuticals (C), Riovant Pharma (C), Teladoc Health (C);
Mark Pennesi, Adverum (C), AGTC (C), Allergan/Editas (C), Astellas Pharmaceuticals (C), Astena (C), Biogen (C), Blue Rock (C), DTx (C), Endogena (C), Eyevensys (C), Gensight (C), Horama (C), Iveric (C), Nacuity Pharmaceuticals (C), Novartis (C), Nyan (C), Ocugen (C), Ora (C), ProQR Therapeutics (C), RegenexBio (C), Roche (C), Sanofi (C), Sparing Vision (C), Vedere (C), Viewpoint Therapeutics (C);
Katarina Stingl, Novartis (F), ProQR (F)